Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung cancer
Not Applicable
Recruiting
- Conditions
- advanced or recurrent non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000006892
- Lead Sponsor
- School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2)plueral, peritoneal, or pericardial effusion requiring drainage 3)active infection 4)unable to take oral medication 5)symptomatic eye disorders 6)pregnant or lactating 7)symptomatic brain metastasis 8)other malignancies 9)uncontrolled diabetes 10) active complications 11)patients whom physicians judged to be unsuitable for enrollment for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method